NC-LENOVO
15.2.2024 15:01:34 CET | Business Wire | Press release
Today, Lenovo™ announced a strategic partnership with Anaconda® Inc., the leading provider of the world’s most popular artificial intelligence (AI), machine learning (ML) and data science platform, to empower Lenovo’s high performance data science workstations. The partnership will couple Lenovo’s trusted ThinkStation™ and ThinkPad™ workstation product portfolio heritage and leadership with Anaconda’s enterprise strengths for open-source leadership, security, and reliability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215334255/en/
Lenovo and Anaconda Announce Agreement to Accelerate AI Development and Deployment (Photo: Business Wire)
The rapidly evolving world of artificial intelligence, deep learning and generative AI is opening up new opportunities for businesses and data scientists. Much of the AI innovation taking place today is driven by open-source software and cloud-based solutions, with Python being a leading software language for AI applications. However, the data security risks associated with utilizing open-source software at an enterprise level, privacy concerns and often prohibitive cost of cloud-based AI solutions, is causing many organizations to rethink their approach to investment in AI development. With Intel®-powered Lenovo workstations architected with the latest generations of professional NVIDIA® GPUs built for large-language model fine-tuning, and the Anaconda Navigator’s ability to enable businesses to leverage open-source and AI with enhanced security, scale, and governance mechanisms in place, the partnership allows data scientists to create and deploy AI solutions with first class hardware and enterprise-grade AI software support within a more manageable investment framework.
Optimized for Intel platforms, Lenovo’s new generation of data science workstations deliver remarkable AI performance and is one of the world’s most powerful and scalable AI workstation portfolios. Planning for AI projects requires clear and thoughtful pathways to allocate the right hardware, software and skillsets to manage each stage of AI development. Lenovo workstations complement cloud-based AI solutions by acting as a bridge between local and cloud resources and aid data scientist flexibility and productivity. Lenovo’s full workstation portfolio includes highly configurable systems designed for nearly every AI workflow, industry or vertical, size and price point – all architected to drive the future of AI forward in an agile and cost-efficient way. From single CPU and GPU mobile workstations that are ideal for data input, collection and preparation, to the most powerful dual CPU and four GPU configurations for advanced AI workflows, Lenovo workstations with Anaconda Navigator offer protected “sandbox” environments to tackle the most complex AI solution development and deployment.
“With Lenovo’s trusted workstation leadership and Anaconda’s trusted leadership in open-source software support and reliability, the partnership is a perfect match,” said Rob Herman, Vice President and General Manager, Workstation and Client AI Group at Lenovo. “We’re excited to activate this partnership to aid data scientists in pushing forward the capabilities of AI with our premium workstations portfolio and Anaconda’s stellar open-source packages and repositories.”
Anaconda Navigator is available for download to use on current and future generation Lenovo Workstations.
“As artificial intelligence and machine learning models grow increasingly complex, high-performance workstations are imperative to empower data scientists with advanced capabilities,” said Chandler Vaughn, Chief Product Officer at Anaconda. “Lenovo's leadership in supplying optimized workstations, featuring robust GPUs, memory, and storage, positions them as an ideal collaborator for Anaconda and our Navigator desktop product. By jointly providing resilient hardware and trusted software tools, Lenovo and Anaconda present data scientists, AI developers, and AI engineers an unrivaled platform to freely explore emerging techniques in AI/ML. This symbiotic relationship enables organizations to push boundaries and accelerate innovations in artificial intelligence without technological constraints.”
For more information about Lenovo’s workstation portfolio, visit www.lenovo.com/workstations.
About Lenovo
Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
About Anaconda
With more than 45 million users, Anaconda is the most popular operating system for AI providing access to the foundational open-source Python packages used in modern AI, data science and machine learning through a seamless platform. We pioneered the use of Python for data science, championed its vibrant community, and continue to steward open-source projects that make tomorrow’s innovations possible. Our enterprise-grade solutions enable corporate, research, and academic institutions around the world to harness the power of open-source for competitive advantage, groundbreaking research, and a better world. To learn more visit anaconda.com or connect on Twitter or LinkedIn.
LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. Anaconda is a registered trademark owned by Anaconda, Inc. Intel is a trademark of Intel Corporation or its subsidiaries in the U.S. and/or other countries. NVIDIA is a trademark of NVIDIA Corporation. Inc. All other trademarks are the property of their respective owners. ©2024 Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215334255/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom